Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009
points should be considered when initiating therapy with PEGINTRON in combination with REBETOL: (1) These indications are based on achieving undetectable HCV-RNA after treatment for 24 or 48 weeks and maintaining a Sustained Virologic Response (SVR) 24 weeks after the last dose. (2) Patients with the following characteristics are less likely to benefit from retreatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and genotype 1 infection. (3) No safety and efficacy data are available for treatment of longer than one year.
PEGINTRON is also indicated for use alone for the treatment of chronic hepatitis C in patients with compensated liver disease previously untreated with interferon alpha and who are at least 18 years of age.
The following points should be considered when initiating therapy with PEGINTRON alone: Combination therapy with REBETOL is preferred over PEGINTRON monotherapy unless there are contraindications to, or significant intolerance of, REBETOL. Combination therapy provides substantially better response rates than monotherapy.
Important Safety Information Regarding U.S. Labeling for PEGINTRON and REBETOL
WARNING: RISK OF SERIOUS DISORDERS AND RIBAVIRIN-ASSOCIATED EFFECTS
Alpha interferons, including PEGINTRON, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many, but not all cases, these disorders resolve after stopping PEGINTRON therapy.
Use with Ribavirin: Ribavirin may cause birth defects and death of the unborn child. Extreme care must be taken to avoid pregnancy in fem
'/>"/>
| SOURCE Schering-Plough Corporation Copyright©2009 PR Newswire. All rights reserved |
Related medicine technology :
1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
(Date:5/19/2013)... , May 19, 2013 The non-surgical ... temperature radiofrequency (RF) energy is effective in control ... reduces the need for medication 10 years post-procedure, ... today at the Digestive Disease Week (DDW) meeting ... . "The sustained improvement ...
(Date:5/18/2013)... 2013 Although colonoscopy exams prevent many colon ... sensitive method for detecting colorectal cancers 2 , the ... 3 . EndoChoice ® Inc. today unveiled research ... the accuracy of this procedure and greatly reduces the ... discussing these clinical trial results and featuring the Fuse ...
(Date:5/18/2013)... , May 18, 2013 The Open ... , Occupy Psychiatry , and leading ... care, announces a social media campaign showcasing video ... psychiatric model, which focuses on pathology and illness ... with the American Psychiatric Association,s (APA) rollout of ...
Breaking Medicine Technology:Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 2New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy 3New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3[0] Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy[0] New Study Shows Full Spectrum Endoscopy Procedure Reduces The 'Miss Rate' of Adenomas During Colonoscopy[0] New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses
... is announcing that it entered into an agreement with Oman ... market Neomycin Sulfate Tablets. Under the terms of the agreement, ... and distributed by Breckenridge on an exclusive basis in the ... Food and Drug Administration (FDA), and the companies began shipping ...
... CLEMENTE, Calif., April 4, 2011 ICU ... that three different clinical studies presented at the Annual ... America (SHEA) April 1-4 in Dallas showed that the ... risk of bacterial contamination and limit the incidence of ...
Cached Medicine Technology:Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections 2Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections 3Three Studies Presented at the 2011 SHEA Annual Scientific Meeting Show That the ICU Medical MicroCLAVE® Contributes to a Significant Decrease in Bacterial Transfer and Reduction in Bloodstream Infections 4(Date:5/19/2013)... May 19, 2013 These molecular ... US, UK, Spain, Japan, Italy, Germany and France:, ... molecular diagnostics laboratory practice, as well as key ... significant market impact during the next five years. ... and biochip technologies, test formats, detection methodologies, trends ...
(Date:5/19/2013)... 19, 2013 Americans live closer to ... newest American Veterinary Medical Association (AVMA) U.S. Pet Ownership ... owners consider their dog a member of the family, ... as much five years earlier. , According to the ... the national income dedicated to pets has increased every ...
(Date:5/19/2013)... Vegas, Nevada (PRWEB) May 19, 2013 ... agency , is proud to announce the launch it's ... Awards at the MGM Grand on 5/19/2013. Consumers traveling ... all new special pricing available on VegasHotelEscapes.com's website. Travelers ... that they beat any competitors price. , Vegas Hotel ...
(Date:5/19/2013)... Passages Malibu, the leading non-12 step, holistic, and ... the launch of a “Sobriety, Health, and Wellness” survey ... “We are always looking for new ways to engage ... regarding sobriety, what’s working for people, and what isn’t,” ... Passages Addiction Treatment Centers located in Malibu and ...
(Date:5/19/2013)... 19, 2013 HealthEconomics.Com , the ... pleased to unveil a new and exciting service: HE-Xpo: ... a powerful array of real-time communication tools to expand ... and abroad. , HE-Xpo is powered by OnStream ... look and feel of being at a physical trade ...
Breaking Medicine News(10 mins):Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 2Health News:Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing 3Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 2Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 3Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3[0] Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com[0] Dogs Becoming Part of the Family: Dog Bite Injuries Decreasing[0] VegasHotelEscapes.com Announces Special Vegas Packages For Billboard Music Awards[0] Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey[0] HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access
... team at Brunel University to help people ridden on wheelchair to ... a day. // ,Presently patients are asked to ... program may soon change all that. It requires only a standard ... ,This would enable doctors to build up information on ...
... The Phase II Clinical Trial conducted by a cancer institute ... for kidney cancer with the help of bevacizumab and erlotinib[1], ... effective and may help in prolonging patient's survival. ... treat, especially once it has started to spread to other ...
... a drug containing parts of diptheria toxin as a way ... //cell of patients suffering from advanced melanoma (Skin Cancer) ... trial to test the drug denileukin diftitox (also known as ... seven patients with stage IV disease experienced significant regression or ...
... Mahathir Mohamad suffered a heart attack Thursday and was admitted ... ,Mahathir, 81, had complained of mild chest pains ... Care Unit (CCU) of the National Heart Institute, the hospital ... agency. ,Mahathir had coronary artery bypass surgery in ...
... software used by doctors, AMA President, Dr Mukesh Haikerwal, ... software packages is expanding rapidly in Australia but the ... of standardised testing of clinical software may create potential ... is calling for a national regulatory framework to standardise ...
... novel method of measuring the risk of heart disease, ... their level of affluence, which also contributes to heart ... often eliminated while studying the risk factors and now ... the inclusion of new parameters, to decide the patients ...
Cached Medicine News:Health News:Pain Tracked By 3D Computer Map 2Health News:Systemic Pre-Surgical Treatment Can Prolong Survival Of Kidney Cancer Patients 2Health News:Systemic Pre-Surgical Treatment Can Prolong Survival Of Kidney Cancer Patients 3Health News:Diptheria Toxin And Interleukin2 Help Killing Melanoma Tumour Cells 2Phaco Chopper, double ended; a combination of a modified MicroFinger and a pointed "quick chop" tip, in titanium...
5mm from bend to tip 0.3x2.0mm Tip, Oblong 2 Sided Straight, at 45 degrees; In Titanium...
Angled 40 Degrees, 0.6x0.8 Elliptical Tip; in Titanium...
Double ended with 0.5mm x 10mm and 1.0mm x 15mm blades; both blades gently curved; round serrated handle, In Titanium....
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |